On the precision oncology front, expanded larotrectinib data will focus on efficacy and safety findings for pediatric and adult patients with NTRK gene fusion-positive solid tumors
COVID-19 Vaccine (DS-5670) in Unvaccinated Individuals in Japan
It´s the first trial to demonstrate the benefits of dual pathway inhibition
WHO and UNICEF call on governments, industry, donors and civil society to fund and prioritize access to assistive products
Bora establishes a leadership position in Taiwan's CDMO sector as it continues to expand into the global CDMO market
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
Ondexxya is the first approved reversal agent specifically for Factor Xa inhibitors, providing a major advance in the treatment of patients hospitalised with life-threatening bleeding
Tardive dyskinesia (TD) is a movement disorder that is characterized by uncontrollable, abnormal and repetitive movements of the face, torso and/or other body parts, which may be disruptive and negatively impact patients
This is the first CAR T cell therapy application filed for the second-line treatment of R/R LBCL in Japan
The facility registration, along with DMF registration and GMP certification provides peace of mind to clients looking to use our iPSCs for clinical and commercial use in the United States, Japan, and other global markets
Subscribe To Our Newsletter & Stay Updated
